Category: FDA

FDA Hearing On ‘Hemp-Derived CBD’ Today

In its written testimony, NORML Deputy Director Paul Armentano encourages the agency to act expeditiously to clarify confusion among both consumers and regulators with regard to the legality of specific CBD products. It further recommends that the FDA provide regulatory guidelines governing product manufacturing, standardization, and quality.

NIDA Acknowledges Drawbacks to Monopoly on Marijuana Supply

Members of the US Senate at a hearing yesterday expressed skepticism in regard to federal policies limiting the ability of investigators to engage in clinical studies of marijuana’s health benefits. Senators heard from representatives from the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), University of Mississippi Medical Center, Arrowhead Regional Medical Center and Project SAM on a variety of issues The hearing’s most noteworthy moment came when Nora Volkow, director of NIDA, acknowledged that the monopoly on marijuana cultivation for research purposes […]

Study: Cannabis May Mitigate Traumatic Memories In Patients With PTSD

[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To have NORML’s news alerts and legislative advisories delivered straight to your in-box, sign up here.] The use of cannabis and cannabinoids appears to mitigate symptoms associated with post-traumatic stress disorder (PTSD), according to a new review of clinical and preclinical evidence published online in the scientific journal Drug Testing and Analysis. An international team of investigators from Germany, the United States, and the United Kingdom reported that the use of cannabis to “dramatically reduced” PTSD […]